Edwards Lifesciences (EW) Q2 2026: TMTT Jumps 45% as Multi-Platform Portfolio Drives Durable Growth
Edwards Lifesciences delivered a 12.5% sales surge in Q2 2026, powered by robust momentum across TAVR, TMTT, and Surgical platforms, with TMTT outpacing expectations at nearly 45% growth. Management raised full-year guidance for all major segments, citing durable, multi-year innovation and expanding global adoption. The company’s long-term outlook is underpinned by a broad pipeline and regulatory catalysts, setting the stage for sustained double-digit growth despite tougher comps ahead.
Summary
- TMTT Acceleration: Mitral and tricuspid therapies led growth, validating Edwards’ multi-therapy strategy.
- Global Platform Strength: TAVR and Surgical segments posted broad-based gains, supporting margin expansion.
- Guidance Lift: Upgraded sales outlook reflects confidence in pipeline, execution, and global demand tailwinds.
Business Overview
Edwards Lifesciences is a global leader in structural heart disease therapies, generating revenue through three primary segments: TAVR (Transcatheter Aortic Valve Replacement), TMTT (Transcatheter Mitral and Tricuspid Therapies), and Surgical Heart Valve Solutions. The company’s business model centers on developing, manufacturing, and commercializing innovative heart valve technologies, with a strong focus on evidence-based adoption and global expansion. TAVR remains the largest segment, but rapid growth in TMTT and a resilient surgical portfolio are increasingly defining the company’s trajectory.
Performance Analysis
Edwards posted 12.5% year-over-year sales growth in Q2 2026, with all product groups and regions contributing to the upside. TAVR delivered 10.5% growth, driven by sustained procedural momentum, stable pricing, and modest market share gains in both U.S. and international markets. The exit of a competitor in Q2 2025 and new clinical evidence further supported TAVR adoption, while the Sapien platform continues to set the standard for valve durability and performance.
TMTT sales surged 44.8% year-over-year, reaching $195.9 million, as differentiated products—Pascal, Evoque, and Sapien M3—drove double-digit procedural growth globally. Each therapy contributed, with Pascal seeing rising adoption for its unique design and clinical outcomes, Evoque scaling rapidly across new and existing centers, and M3 expanding its indication set. Surgical sales rose 5% on the strength of Resilia tissue therapies and new product launches. Gross margin held steady despite foreign exchange headwinds, while disciplined SG&A and R&D investment supported operating leverage.
- Segment Mix Shift: TMTT’s outperformance highlights a growing contribution from newer therapies, reducing dependence on TAVR alone.
- Margin Dynamics: Operating margin expanded to 30%, aided by phasing of investments and lower manufacturing costs offsetting FX pressure.
- Capital Allocation: The company ended the quarter with $2.9 billion in cash and maintains a $1.5 billion buyback authorization, prioritizing organic growth and targeted M&A.
The quarter’s results reflect not just cyclical strength but the impact of sustained R&D, commercial execution, and platform diversification. Management’s guidance increase signals confidence in both near-term delivery and the durability of the growth algorithm.
Executive Commentary
"We delivered stronger than expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio... These underpins are annual sales growth targeting 10%, on average, alongside operating margin expansion for the company, with TAVR growing mid to high single digits."
Bernard Zovighian, Chief Executive Officer
"Adjusted EPS of 78 cents in the quarter benefited from our better than expected top line performance, as well as our planned phasing of strategic investments in R&D and SG&A throughout the year... We continue to expect full year operating margin to be at the high end of the original 28% to 29% guidance, resulting in approximately 150 basis points of constant currency operating margin expansion for the full year."
Doretta Mistras, Chief Financial Officer
Strategic Positioning
1. Multi-Platform Growth Engine
Edwards’ strength now rests on a diversified portfolio—TAVR, TMTT, and Surgical—delivering growth across all regions. TAVR’s position as the benchmark platform is reinforced by clinical data and technology upgrades, while TMTT’s rapid uptake demonstrates the value of offering multiple, complementary therapies for complex patient populations.
2. Evidence-Based Market Expansion
Investment in clinical trials and real-world data is central to Edwards’ strategy, with ongoing studies like PROGRESS (moderate AS) and new indications (asymptomatic, tricuspid) poised to unlock future growth. The company’s ability to shape guidelines and expand patient access is a key differentiator.
3. Global Adoption and Regulatory Tailwinds
International momentum is accelerating, with Europe and Japan both benefiting from updated guidelines and new approvals. The anticipated U.S. TAVR NCD update and pending product launches (Pascal tricuspid, Sapien X4S, Ecliptis) represent near-term catalysts that could expand addressable markets and streamline patient access.
4. Operating Leverage and Capital Discipline
Margin expansion is being delivered through disciplined investment, careful cost control, and a focus on high-return R&D. The company’s capital allocation priorities remain unchanged: organic growth, manufacturing network investment, selective M&A, and opportunistic buybacks.
5. Pipeline Visibility and Layered Growth
Edwards is executing on a roadmap of multi-year growth drivers, with TMTT targeting $2 billion revenue by 2030 and Surgical launching new tissue and adjunctive therapies. The company is positioned to benefit from gradual adoption curves and incremental indications, providing visibility beyond short-term cycles.
Key Considerations
Edwards’ Q2 performance reflects the compounding impact of broad-based innovation, commercial execution, and a robust evidence-generation engine. The company is navigating tougher second-half comps but remains confident in its ability to deliver double-digit growth, margin expansion, and capital returns.
Key Considerations:
- TMTT Outperformance: Broad-based adoption of Pascal, Evoque, and M3 is accelerating TMTT’s path to $2 billion revenue, with new indications and launches layering in future growth.
- TAVR Market Dynamics: Competitive exits, new clinical evidence, and regulatory updates are driving stable share gains, but the pace of market expansion will be shaped by physician behavior and guideline changes.
- Margin Management: Foreign exchange and tax headwinds are being offset by lower manufacturing costs and disciplined SG&A and R&D investment, supporting operating leverage.
- Regulatory Catalysts: U.S. TAVR NCD update, PROGRESS trial results, and new product launches (Pascal tricuspid, Ecliptis) are near-term events that could accelerate adoption and expand addressable markets.
- Capital Allocation: Focus remains on organic growth and manufacturing, with a healthy balance sheet enabling continued share repurchases and targeted M&A.
Risks
Key risks include delayed or unfavorable regulatory decisions (notably the U.S. TAVR NCD), slower-than-expected adoption of new indications, and potential pricing or reimbursement pressure in major markets. Foreign exchange volatility, incremental tax headwinds, and competitive reentry in TAVR or TMTT could also impact growth and margin trajectory. Management’s guidance incorporates conservative adoption curves for new indications, but execution risk remains as the company scales new therapies globally.
Forward Outlook
For Q3 2026, Edwards guided to:
- Sales of $1.63 to $1.71 billion
- Adjusted EPS of $0.71 to $0.77
For full-year 2026, management raised guidance to:
- Sales growth of 10% to 11% (previously 9% to 11%)
- TAVR sales growth of 8% to 9%
- TMTT revenue of $760 to $780 million
- Adjusted EPS of $2.95 to $3.05
Management highlighted several factors that will shape the back half:
- Second-half comps are tougher due to an unusually strong 2025
- Q3 will reflect normalized seasonality, with less summer upside than last year
- Upcoming regulatory and clinical milestones could drive incremental upside in 2027 and beyond
Takeaways
Edwards Lifesciences enters the second half of 2026 with a multi-platform growth engine, strong execution, and a pipeline of regulatory and clinical catalysts.
- Portfolio Diversification: TMTT’s rapid growth and broad-based adoption reduce reliance on TAVR, while Surgical continues to deliver steady gains.
- Margin Expansion: Operating leverage is being realized even as the company invests in long-term growth opportunities.
- Pipeline Visibility: Investors should watch for the impact of the U.S. TAVR NCD update, PROGRESS trial results, and new product launches to shape the next phase of Edwards’ growth story.
Conclusion
Edwards Lifesciences’ Q2 2026 results confirm that its innovation-driven, multi-platform strategy is delivering durable growth and margin expansion. With upgraded guidance and a robust pipeline, the company is well-positioned to sustain double-digit growth and shareholder returns, even as it navigates tougher comps and evolving regulatory dynamics in the quarters ahead.
Industry Read-Through
Edwards’ outperformance in TMTT and stable TAVR growth signal an inflection for the structural heart industry, with evidence-based adoption and portfolio breadth emerging as key competitive moats. The accelerating uptake of mitral and tricuspid therapies suggests that multi-therapy platforms are gaining traction, raising the bar for single-product competitors. Regulatory and guideline shifts—such as the U.S. TAVR NCD update and new data on moderate AS—are likely to reshape referral patterns and expand addressable markets, benefiting those with strong evidence and broad product offerings. Investors in cardiac device and medtech peers should monitor Edwards’ execution on layered growth, capital allocation discipline, and the pace of adoption for new indications as bellwethers for sector momentum.